Brian Sweet

Experienced executive pharmacy leader with a forward-thinking approach and more than 20 years of expertise in HEOR, RWE, RWD partnerships, and value demonstration.

Role: Executive Director, Health Economics & Outcomes Research at Geron Corporation
Location: Naples, FL, US
LinkedIn followers: 500 followers

Healthcare & Human ServicesView LinkedIn profile

About Brian Sweet

I am a healthcare executive with more than three decades of leadership experience driving…

Experience

Executive Director, Health Economics & Outcomes Research
Geron Corporation
Mar 2025 — Present · Naples, FL, US
Designing and leading the execution of a global, comprehensive, and scientifically rigorous HEOR program that is aligned with the clinical, commercial, and market access strategies.

Education

University at Buffalo
B.S. Pharmacy
University at Buffalo
Masters in Business Administration

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
b•••••@geron.com
Personal email
•••••@•••••.com
Direct dial
+17•••••••98

Unlock verified contacts

Free to start · No credit card required

Current company

Geron Corporation

Biotechnology Research · 371 employees · Founded 1992 · Foster City, California, United States

Geron is a biopharmaceutical company that is charting a new course with the goal to deliver innovative treatment options for people living with blood cancer. Our tireless pursuit to improve outcomes for these patients resulted in the U.S. approval of the first ever telomerase inhibitor for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. As the sole company with an oligonucleotide telomerase inhibitor approved by the FDA, we feel a deep urgency to bring the potential power of telomerase inhibition to patients in need. We are conducting research in other blood cancers with high unmet need beyond LR-MDS, with ongoing clinical trials across other hematologic malignancies, including a pivotal Phase 3 clinical trial in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF). We are proud of the impact this Nobel-winning science is having in the fight against blood cancers. At Geron, we are united by a shared purpose: Every individual in every role can meaningfully contribute to our mission to change lives by changing the course of blood cancer. With a culture rooted in courage and determination, we will continue to innovate and pursue new possibilities for patients. To learn more, visit www.geron.com. Geron’s Community Guidelines: https://www.geron.com/CommunityGuidelines/

geron.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About Brian Sweet

Experience

Executive Director, Health Economics & Outcomes Research

Education

University at Buffalo

University at Buffalo

Find verified contacts for anyone on LinkedIn